SEC inquiry
This article was originally published in The Tan Sheet
Executive Summary
Schering receives "Wells Notice" March 11 notifying firm of SEC staff decision to recommend the commission bring a civil action against firm and CEO Richard Kogan regarding Oct. 3 earnings warning, which was preceded by closed-door investor meetings (1"The Tan Sheet" Nov. 18, 2003, p. 13). Schering can now file legal brief...
You may also be interested in...
Schering’s Rocky Succession: Former Mining Exec To Head CEO Search
Schering-Plough interim Chairman Richard Osborne is likely to be wary of mergers as a turnaround strategy for the company
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.